
    
      OUTLINE: Patients receive abiraterone acetate orally (PO) once daily (QD) or enzalutamide PO
      QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21
      days for 2 years in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days.
    
  